IGF2BP2 and ovarian carcinoma: Inhibition of IGF2BP2 with a novel small molecule, CWI1‐2, has an antitumor effect in AML cells.[44] JX5, another small molecule inhibitor of IGF2BP2 acts against T‐ALL cell proliferation.[151] An inhibitor of another m6A reader, IGF2BP3, shows promise in ovarian cancer treatment.